Avrupa Birliği - Slovence - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 in 5.

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - montelukast - žvečljiva tableta - montelukast 4 mg / 1 tableta - montelukast

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - montelukast - žvečljiva tableta - montelukast 5 mg / 1 tableta - montelukast

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

generics (uk) ltd. - montelukast - žvečljiva tableta - montelukast 4 mg / 1 tableta - montelukast

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

generics (uk) ltd. - montelukast - žvečljiva tableta - montelukast 5 mg / 1 tableta - montelukast

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologi - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

filmsko obložena tableta - risedronska kislina

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

takeda manufacturing austria ag - c1 inhibitor (človeški) - angioedem, dedno - c1-inhibitor, plazma izhajajo, zdravil, ki se uporabljajo v dedno angioedema - zdravljenje in preprečevanje napadov angioedemov pri odraslih, mladostnikih in otrocih (starih 2 leti ali več) z dednim angioedemom (hae). rutinsko preprečevanje angioedema napadov pri odraslih, mladostnikih in otrocih (6 let in več) s hudimi in ponavljajočimi se napadi dedno angioedema (hae), ki so nestrpni do ali nezadostno zaščitena z ustno preprečevanje zdravljenje, ali pri bolnikih, ki so neustrezno upravlja s ponovljenimi akutno zdravljenje.